Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05326269
Other study ID # NMRR-16-1985-331
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 23, 2017
Est. completion date September 15, 2019

Study information

Verified date April 2022
Source Hospital Kemaman
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The trial was to determine the effect of administrating subcutaneous terbutaline prior to emergency caesarean delivery for suspected fetal distress


Description:

The trial was a double-blinded, placebo-controlled study using subcutaneous terbutaline for acute tocolysis prior to emergency caesarean delivery in suspected fetal distress. The intervention (subcutaneous terbutaline) was compared to placebo looking at the neonatal and maternal outcomes. The primary outcome was the proportion of babies with neonatal acidosis (based on umbilical artery blood sampling at delivery). Other outcome of interest were the mean cord pH and base excess, the Apgar score at 5 minutes after delivery, he proportion of babies requiring intubation and admission to the Neonatal Intensive Care Unit. The maternal outcomes of interest were the changes in mean arterial pressure (before and after the drug or placebo injection), the maternal heart rate changes, the estimated blood loss, and the hematocrit changes.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date September 15, 2019
Est. primary completion date September 15, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - term singleton pregnancy - cephalic presentation - in labour with cervix dilatation > 4cm and regular uterine contractions of 3 or more 10 min - abnormal fetal heart rate status diagnosed using standard electronic FHR according to NICE guideline (2014) - acceptance of participation by the signing of a written consent. Exclusion Criteria - maternal cardiopathy - hyperthyroidism - abruptio placentae or other placental accidents - hypertensive disease of pregnancy - hyperstimulation with oxytocin - multiple gestation - abnormal fetus planned for conservative management - evidence of intrauterine growth restriction - patient on medication which will interact with terbutaline (tricyclic antidepressants, beta-blockers, diuretics and sympathomimetic medicine).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Terbutaline
Subcutaneous injection

Locations

Country Name City State
Malaysia Hospital Kemaman Kuala Terengganu Terengganu

Sponsors (1)

Lead Sponsor Collaborator
Hospital Kemaman

Country where clinical trial is conducted

Malaysia, 

References & Publications (6)

Buckley VA, Wu J, De Vries B. Outcomes following acute tocolysis prior to emergency caesarean section. Aust N Z J Obstet Gynaecol. 2020 Dec;60(6):884-889. doi: 10.1111/ajo.13170. Epub 2020 May 6. — View Citation

Ingemarsson I, Arulkumaran S, Ratnam SS. Single injection of terbutaline in term labor. I. Effect on fetal pH in cases with prolonged bradycardia. Am J Obstet Gynecol. 1985 Dec 15;153(8):859-65. — View Citation

Leathersich SJ, Vogel JP, Tran TS, Hofmeyr GJ. Acute tocolysis for uterine tachysystole or suspected fetal distress. Cochrane Database Syst Rev. 2018 Jul 4;7:CD009770. doi: 10.1002/14651858.CD009770.pub2. Review. — View Citation

Magann EF, Cleveland RS, Dockery JR, Chauhan SP, Martin JN Jr, Morrison JC. Acute tocolysis for fetal distress: terbutaline versus magnesium sulphate. Aust N Z J Obstet Gynaecol. 1993 Nov;33(4):362-4. — View Citation

Patriarco MS, Viechnicki BM, Hutchinson TA, Klasko SK, Yeh SY. A study on intrauterine fetal resuscitation with terbutaline. Am J Obstet Gynecol. 1987 Aug;157(2):384-7. — View Citation

Pullen KM, Riley ET, Waller SA, Taylor L, Caughey AB, Druzin ML, El-Sayed YY. Randomized comparison of intravenous terbutaline vs nitroglycerin for acute intrapartum fetal resuscitation. Am J Obstet Gynecol. 2007 Oct;197(4):414.e1-6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Neonatal acidosis Umbilical artery acidosis within 1 hour of delivery
Secondary Neonatal acid base status Mean umbilical artery pH & base excess within 1 hour of delivery
Secondary Neonatal Apgar score Mean Apgar score at 5 minutes of life 5 minutes after delivery
Secondary Neonatal intensive care unit admission Number of babies admitted to neonatal intensive care unit Within 24 hours of delivery
Secondary Maternal blood pressure Mean maternal arterial pressure (before and after drug or placebo administration) Within 1 hours after drug administration
Secondary Maternal heart rate Mean maternal heart rate changes (before and after drug or placebo administration) Within 1 hours after drug administration
Secondary Blood loss Mean estimated blood loss Within 24 hours of delivery
Secondary Hematocrit change Mean hematocrit changes before and after cesarean section Within 24 hours of delivery
See also
  Status Clinical Trial Phase
Completed NCT01680484 - Bitter Chocolate or Orange Juice for Non-reactive Non-stress Test (NST) Patterns N/A